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Summary A total of 61 eligible patients with metastatic cancer have been treated in a series of Phase II trials
of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were colorectal (23), renal (21), and non
small cell lung (17). No patient had received prior chemotherapy.
The drug was given intravenously as a 20 min infusion at the dose of 120 mg-2 on days 1 to 5 every 3
weeks. Treatment was well tolerated; the only significant side effects being mild nausea and generalised
musculo-skeletal pains.
Response was assessed after two cycles of therapy. No patient achieved an objective partial response. A
total of nine patients demonstrated stable disease for a median duration of 11 weeks.
Using this schedule of administration, fosquidone has no significant antitumour activity in this group of
tumours.
Fosquidone is a water soluble analogue of the drug mito-
quidone, which was the first of a series of pentacyclic pyrro-
loquinones developed as anti-tumour agents. Mitoquidone
was of particular interest because of its broad spectrum of
activity in rodent solid tumours and xenografts with no
demonstrable activity in P388 or L1210 leukaemia (Fenton et
al., 1989). The basis of its antitumour efficacy was unknown
but these characteristics suggested a different mechanism of
action from that of conventional cytotoxic agents. Phase I
trials with Mitoquidone were closed prematurely because of
solubility problems, and the possible occurrence of intravas-
cular drug precipitation (Speth et al., 1988). However anti-
tumour efficacy had been recorded in one patient before the
study closed.
Fosquidone has similar biological characteristics to the
parent compound, and is much more soluble by virtue of its
phosphate side chain. A particular feature of preclinical
studies was its schedule-dependency in solid tumours; daily
repeated i.v. administration was more effective than high
dose intermittent administration. Antitumour activity in
human tumour xenografts was seen in breast, ovary, colon
and head and neck tumours (Fenton et al., 1989).
Phase I trials with Fosquidone were conducted with three
schedules; single dose weekly, daily for 5 days every 3 weeks,
and three times per week for 3 consecutive weeks (Cassidy et
al., 1989; Smyth et al., 1990; Planting et al., 1990). The
maximum tolerated dose was 250 mg m-2 for the 5 day
schedule; at this level headache as well as pain sometimes at
the site of tumour or metastases, were dose-limiting. Minor
clinical responses were reported in three patients (with lung,
head and neck and colonic tumours).
The schedule which was chosen for this Phase II study was
the daily for 5 days schedule, and this was selected for the
following reasons.
(a) This schedule permits regular, frequent administration
of Fosquidone.
(b) At this dose level in the Phase I trial toxicity was
minor, comprising WHO grade 1 or 2 nausea and
vomiting and grade 1 or 2 headache.
(c) At this dose level, the measured AUC after each daily
dose (9-29 1tg ml-' min'1) was in excess of that
recorded at the tumoricidal dose in the rat hepatoma
model (Smyth et al., 1990).
A Phase II programme was therefore initiated in which the
Early Clinical Trials Group of the EORTC co-operated with
the Phase II Trials Committee of the Cancer Research Cam-
paign in the UK. This study reports the Phase II trials in the
following tumour types performed by the CRC Phase II
Committee: colon, non small cell lung and kidney.
Patients and methods
Eligibility criteria included histologically proven and measur-
able and/or evaluable advanced disease, WHO performance
status of 0, 1 or 2; age up to 75 years; and adequate bone
marrow, hepatic and renal function. Patients should not have
received prior chemotherapy.
Treatment was given as an i.v. infusion over 20min, on
days 1-5 of a 3 week cycle, at the dose of 120 mgm2 per
day. The drug was diluted in 5% dextrose to a final concen-
tration not exceeding 2.0 mg ml-'.
Patients were scheduled to receive at least two courses of
chemotherapy, and to assess activity for each tumour type at
least 14 cases were required.
Response assessment was made by repeated clinical and
radiological examinations as appropriate. Complete and par-
tial responses, stable and progressive disease were defined by
agreed WHO criteria. Patients who demonstrated evident
tumour progression after one course of treatment discon-
tinued at that stage and were classified as 'early progression'.
Results
A total of 70 patients were entered into the Phase II trials; 26
patients with colon cancer, 18 with non small cell lung, and
26 with renal cancer. Of the 70 patients entered, nine were
deemed ineligible. The reasons were inadequate bone marrow
or renal function in seven, prior chemotherapy in one and no
histological confirmation of cancer in one case.
The distribution of patients and details of characteristics
according to tumour type are given in Table I. A total of 143
complete courses of treatment were given, and the break-
down in tumour type is also given in Table I. Of the 61
eligible patients, 22 received one course only, 16 received two
courses and 23 received three or more complete courses. The
maximum number received was six courses.
Responses assessed after two courses are given in Table II.
Also included are 15 patients with 'early progression' after
one cycle of treatment only. A further five patients were
Correspondence: S.B. Kaye.
Received 4 November 1991; accepted 5 December 1991.
Br. J. Cancer (1992), 65, 624-625 '." Macmillan Press Ltd., 1992PHASE II TRIALS OF FOSQUIDONE 625
Table I Patient characteristics
Study
Non small
Colon cell lung Renal
Number of patients 26 18 26
Number eligible 23 17 21
Sex: Male/Female 12/11 14/3 16/5
Median age (range) 53 (40-74) 57 (45-74) 57 (29-72)
WHO Performance status
0 12 4 3
1 10 12 14
2 1 1 4
Total number of completed 55 32 56
courses
Table II Response evaluation
Study
Response Colon Non small cell lung Renal
CR 0 0 0
PR 0 0 0
NC 5 1 3
Progression 12 6 14
'Early progression' 4 7 4
Not evaluable 2 3 0
defined as 'non evaluable' because they either did not receive
one complete cycle or were not adequately reassessed at the
appropriate time. A total of nine patients achieved stable
disease for a median duration of 11 weeks.
Treatment was well tolerated. Haematological toxicity was
absent. Nausea and vomiting occurred with approximately
40% of courses, but was generally Grade 1 or 2 in severity.
Musculo skeletal pain was noted with approximately 30% of
courses, and 25% of courses were associated with mild or
moderate headaches. In two cases treatment was stoppped
because of generalised pain and headache and in one case
because of chest pain, but symptoms of this severity were
exceptional. Other occasional findings included irritation at
the site of injection, a degree of malaise or fatigue, and
exacerbation of pain at disease sites.
Discussion
Analysis of these Phase II studies has revealed no significant
activity for Fosquidone, when using a 5 daily schedule every
3 weeks, despite the fact that none of the patients treated had
received prior chemotherapy.
The experimental antitumour efficacy of Fosquidone re-
mains unexplained. The drug was inactive when tested in
vitro in a number of cell lines, while clearly effective in vivo in
several tumour models (Fenton et al., 1989). Possible
explanations could include metabolic conversion to an active
species, or else the involvement of immunomodulatory or
vascular mechanisms, but experimental data in support of
any of these hypotheses are not yet available. Another strik-
ing feature of the drug's experimental activity is its clear
schedule dependency, with long term exposure being the most
effective in murine tumour models. For this reason additional
Phase I trials have been initiated in an attempt to simulate
the experimentally active schedules, using long term infusions
and also orally formulated Fosquidone. However, further
development of antitumour agents based on the pentacyclic
pyrroloquinone structure may depend on a clearer under-
standing of the basis for its activity.
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